Pathology: la/mBC - HR positive - L2 - all population; la/mBC - HR positive - L2 - PIK3CA mutant; la/mBC - HR-positive - 2nd line (L2);
| la/mBC - HR positive - L2 - all population | la/mBC - HR positive - L2 - PIK3CA mutant | la/mBC - HR-positive - 2nd line (L2) | ||||
| BELLE-2 (full population), 2017 | BELLE-2 (PI3K pathway activated), 2017 | SOLAR-1 (patients with PIK3CA mutant status), 2019 | SOLAR-1 (patients without PIK3CA mutant status), 2019 | BELLE-3, 2018 | ||
| buparlisib plus fulvestrant | 3 | T1 | T1 | T1 | ||
| alpelisib plus fulvestrant | 2 | T1 | T1 | |||
| fulvestrant | 0 | T0 | T0 | T0 | T0 | T0 |